Cargando…

High-Content Analysis-Based Sensitivity Prediction and Novel Therapeutics Screening for c-Met-Addicted Glioblastoma

SIMPLE SUMMARY: Real-time ex vivo drug testing tailors individual therapeutics based on predicted drug responses. Most technologies to date rely on conventional drug screening that provides low confidence data. Here, we present high-content analysis-based drug testing of glioblastoma patients to ide...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oh, Jeong-Woo, Oh, Yun Jeong, Han, Suji, Her, Nam-Gu, Nam, Do-Hyun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7864197/ https://www.ncbi.nlm.nih.gov/pubmed/33498427 http://dx.doi.org/10.3390/cancers13030372

Ejemplares similares

The Protein Neddylation Inhibitor MLN4924 Suppresses Patient-Derived Glioblastoma Cells via Inhibition of ERK and AKT Signaling
por: Han, Suji, et al.
Publicado: (2019)

Potent effect of the MDM2 inhibitor AMG232 on suppression of glioblastoma stem cells
por: Her, Nam-Gu, et al.
Publicado: (2018)

Therapeutic Efficacy of ABN401, a Highly Potent and Selective MET Inhibitor, Based on Diagnostic Biomarker Test in MET-Addicted Cancer
por: Kim, Jooseok, et al.
Publicado: (2020)

WNT Signaling as a Therapeutic Target for Glioblastoma
por: Latour, Michael, et al.
Publicado: (2021)

Targeting the epithelial to mesenchymal transition in glioblastoma: the emerging role of MET signaling
por: Lee, Jin-Ku, et al.
Publicado: (2014)

Tumor Inhibitory Effect of IRCR201, a Novel Cross-Reactive c-Met Antibody Targeting the PSI Domain
por: Park, Hyunkyu, et al.
Publicado: (2017)

Natural killer (NK) cells inhibit systemic metastasis of glioblastoma cells and have therapeutic effects against glioblastomas in the brain
por: Lee, Se Jeong, et al.
Publicado: (2015)

Glioblastoma specific antigens, GD2 and CD90, are not involved in cancer stemness
por: Woo, Seon Rang, et al.
Publicado: (2015)

Integrated pharmaco-proteogenomics defines two subgroups in isocitrate dehydrogenase wild-type glioblastoma with prognostic and therapeutic opportunities
por: Oh, Sejin, et al.
Publicado: (2020)

Novel c-Met inhibitor suppresses the growth of c-Met-addicted gastric cancer cells
por: Park, Chi Hoon, et al.
Publicado: (2016)

Role and Therapeutic Targeting of the HGF/MET Pathway in Glioblastoma
por: Cruickshanks, Nichola, et al.
Publicado: (2017)

cIRCR201-dPBD, a Novel Pyrrolobenzodiazepine Dimer-Containing Site-Specific Antibody–Drug Conjugate Targeting c-Met Overexpression Tumors
por: Min, Byeongkwi, et al.
Publicado: (2020)

Erratum: Cuvette-Type LSPR Sensor for Highly Sensitive Detection of Melamine in Infant Formulas. Sensors 2018, 19(18), 3839
por: Oh, Seo Yeong, et al.
Publicado: (2019)

Expression of c-Met Is Different along the Location and Associated with Lymph Node Metastasis of Head and Neck Carcinoma
por: Choe, Ji-Young, et al.
Publicado: (2012)

The role of c-MET inhibitors in advanced hepatocellular carcinoma: now and future
por: Woo, Hyun Young, et al.
Publicado: (2020)

Cuvette-Type LSPR Sensor for Highly Sensitive Detection of Melamine in Infant Formulas
por: Oh, Seo Yeong, et al.
Publicado: (2019)

Multimodal Therapeutic Effects of Neural Precursor Cells Derived from Human-Induced Pluripotent Stem Cells through Episomal Plasmid-Based Reprogramming in a Rodent Model of Ischemic Stroke
por: Oh, Seung-Hun, et al.
Publicado: (2020)

New Preclinical Development of a c-Met Inhibitor and Its Combined Anti-Tumor Effect in c-Met-Amplified NSCLC
por: Kim, Nam Ah, et al.
Publicado: (2020)

Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification
por: Wang, Jieyi, et al.
Publicado: (2016)

Glioblastoma and Methionine Addiction
por: Sowers, Mark L., et al.
Publicado: (2022)

Identification of MET fusions as novel therapeutic targets sensitive to MET inhibitors in lung cancer
por: Sun, Dantong, et al.
Publicado: (2023)

In vivo RNAi screen identifies NLK as a negative regulator of mesenchymal activity in glioblastoma
por: Sa, Jason K., et al.
Publicado: (2015)

Expression of c-MET in Invasive Meningioma
por: Yun, Sumi, et al.
Publicado: (2015)

Truncated RAF kinases drive resistance to MET inhibition in MET-addicted cancer cells
por: Petti, Consalvo, et al.
Publicado: (2014)

Glioblastoma patient-derived cell-based phenotypic drug screening and identification of possible action mechanisms through proteomic analysis
por: Kim, Young Eun, et al.
Publicado: (2021)

Beyond Substance Addiction: Broadening the Concept of Addiction to Include Behavioral Addiction
por: Kim, Ji Hyun, et al.
Publicado: (2013)

Azathioprine antagonizes aberrantly elevated lipid metabolism and induces apoptosis in glioblastoma
por: Nam, Hye Jin, et al.
Publicado: (2021)

Novel Semi-Replicative Retroviral Vector Mediated Double Suicide Gene Transfer Enhances Antitumor Effects in Patient-Derived Glioblastoma Models
por: Lee, Mijeong, et al.
Publicado: (2019)

Solubility Determination of c-Met Inhibitor in Solvent Mixtures and Mathematical Modeling to Develop Nanosuspension Formulation
por: Ravi, Maharjan, et al.
Publicado: (2021)

KML001, a Telomere-Targeting Drug, Sensitizes Glioblastoma Cells to Temozolomide Chemotherapy and Radiotherapy through DNA Damage and Apoptosis
por: Woo, Seon Rang, et al.
Publicado: (2014)

The role of c-Met and VEGFR2 in glioblastoma resistance to bevacizumab
por: Carvalho, Bruno, et al.
Publicado: (2021)

USP8 modulates ubiquitination of LRIG1 for Met degradation
por: Oh, Young Mi, et al.
Publicado: (2014)

Mutation-specific non-canonical pathway of PTEN as a distinct therapeutic target for glioblastoma
por: Choi, Seung Won, et al.
Publicado: (2021)

Soluble cMet levels in urine are a significant prognostic biomarker for diabetic nephropathy
por: Kim, Yong Chul, et al.
Publicado: (2018)

Secretome analysis of patient-derived GBM tumor spheres identifies midkine as a potent therapeutic target
por: Han, Suji, et al.
Publicado: (2019)

Correction: Secretome analysis of patient-derived GBM tumorspheres identifies midkine as a potent therapeutic target
por: Han, Suji, et al.
Publicado: (2020)

c-MET as a Potential Therapeutic Target in Ovarian Clear Cell Carcinoma
por: Kim, Ha-Jeong, et al.
Publicado: (2016)

Aptamer-Modified Erythrocyte Membrane-Coated pH-Sensitive Nanoparticles for c-Met-Targeted Therapy of Glioblastoma Multiforme
por: Liu, Xianping, et al.
Publicado: (2022)

Patient-derived exosomes facilitate therapeutic targeting of oncogenic MET in advanced gastric cancer
por: Hyung, Sujin, et al.
Publicado: (2023)

Sensitivity to PRIMA-1(MET) is associated with decreased MGMT in human glioblastoma cells and glioblastoma stem cells irrespective of p53 status
por: Patyka, Mariia, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_gqchai4lhis2hiaq041vrilsn9